TrialPLoS medicine2025

Dalpiciclib combined with pyrotinib and endocrine therapy in women with ER-positive, HER2-positive advanced breast cancer: A prospective, multicenter, single-arm, phase 2 trial.

Jian Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.